about
Clinical potential of pacritinib in the treatment of myelofibrosisThe impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.Application of single-cell genomics in cancer: promise and challengesImpact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferationAdult idiopathic thrombocytopenic purpura.Practical management of patients with myelofibrosis receiving ruxolitinib.Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21Single-cell RNA sequencing reveals molecular and functional platelet bias of aged haematopoietic stem cells.Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathwaysFLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.Distinct myeloid progenitor-differentiation pathways identified through single-cell RNA sequencing.Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.Initial seeding of the embryonic thymus by immune-restricted lympho-myeloid progenitorsAllogeneic stem cell transplantation for myelofibrosis in 2012.Myeloproliferative neoplasm stem cells.Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidenceErythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fateA dynamic niche provides Kit ligand in a stage-specific manner to the earliest thymocyte progenitors.The earliest thymic T cell progenitors sustain B cell and myeloid lineage potential.Single cell analysis of normal and leukemic hematopoiesis.Persistent malignant stem cells in del(5q) myelodysplasia in remission.HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.Impact of isolated germline JAK2V617I mutation on human hematopoiesis.Lymphomyeloid contribution of an immune-restricted progenitor emerging prior to definitive hematopoietic stem cells.Molecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model.Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease.Mbd3/NuRD controls lymphoid cell fate and inhibits tumorigenesis by repressing a B cell transcriptional program.Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.Equivalence of BCSH and WHO diagnostic criteria for ET.Equivalence of BCSH and WHO diagnostic criteria for ET.Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy.Guideline for the diagnosis and management of myelofibrosis.
P50
Q26796450-F1CFBF04-A0C3-425E-A73A-F3592A1B1960Q27851416-774AD7FD-D30D-4E11-BCAF-BF2692F3C20AQ28085411-B08433E1-4ACB-4310-85EE-7C5556DFCAC4Q28585509-7ECEDBCE-D322-48D7-B7D6-76A02B41B5E3Q33358032-3E3A31AA-76D2-4A6C-BB6A-41A3425C7758Q33410649-C61B2D98-B420-4AF6-B82B-3BA59C2E25E9Q33421596-CB1980A1-5842-4B78-9AFC-9ABF7D540876Q33440361-6C3EC317-D718-4E69-B595-ADCEA4F1AF07Q33886530-C33789A9-1077-4C0D-A392-9062A1E29603Q35407362-BCAFB623-3D94-4672-9FF5-4213C390645BQ36378527-D36F614A-5B21-4278-900F-98D75623082AQ36765250-D04CCE3E-730B-4ADF-8184-63B7D530541DQ36867216-0A08D11D-281E-45B8-AABC-01F0AA2DAAD9Q36982190-BAEFEF10-09DD-407C-83A3-CF31924B50A5Q37149704-F41830FF-6EAF-494C-B5EE-8F40F140DD61Q37179007-9128640E-ADE5-4E85-9F24-4FF6A1DD1654Q37519602-3A4B64DA-25C6-4256-8AF3-4611B4A4503CQ37998567-879F1B96-B5B2-4595-B620-DBFD6E59B3E7Q39118859-181D3FE9-CBA4-461B-80F0-B42C945A5FDCQ39554738-56362311-D66F-40EA-B5C0-408F18B2456CQ41945134-CA9187D6-ECFF-483E-A675-6E635D65B536Q42078769-86EF4697-C8C4-48E1-84D0-868B88A5B0ABQ42140288-C5665725-738B-4080-BA01-C54D75B30661Q42777547-16CF0790-CA6C-4762-A629-0D0228E138DEQ42913764-9DF1B780-C640-4DA8-B37E-F4C58E0FCB1BQ43108048-FF16628B-A128-45AE-A87E-AA243E322101Q43748899-5508FE98-AC60-4397-9CB3-46EF19A5170EQ45856689-BC09D0AF-3913-41BE-B5F1-7968B530063AQ45876973-5310388F-2990-4537-8EBE-FA387EC6C62DQ46701464-7DF2B768-1031-4557-9256-E9B106C2D3DBQ46835143-928A2A29-D3F4-4FD5-94F3-D9D8ACD7EF8DQ47297141-BCD9F36F-93BD-414A-9B09-AD7CBD2F4648Q48144472-844225B7-3657-47DC-820A-02998822A140Q50092012-A6239930-4DCE-4059-8B7E-D34423500CBCQ50202465-16EE15D2-9BB7-42DF-9672-54FA0EDC26CEQ50213969-BEAE61C5-4668-4A2F-B038-3F8F9E34D572Q50453985-88D79E0F-3D3D-4190-8555-47FFD80DA134Q50454348-89DD37CE-4BD2-43FC-88A4-C1167C706F37Q50475109-C7123DC0-E576-40FF-BEC0-374DA2CBD3BAQ50495964-333FB41D-6797-4073-A92F-57A87AF86EF8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Adam J Mead
@ast
Adam J Mead
@en
Adam J Mead
@es
Adam J Mead
@nl
type
label
Adam J Mead
@ast
Adam J Mead
@en
Adam J Mead
@es
Adam J Mead
@nl
prefLabel
Adam J Mead
@ast
Adam J Mead
@en
Adam J Mead
@es
Adam J Mead
@nl
P106
P21
P31
P496
0000-0001-8522-1002